drugset
Drugs / Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions
last change May 2026 re-read 3 minutes ago

Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions

Cell therapy

Developed for
acute myeloid leukemia
Investigated by
Michael Pulsipher · Nationwide Children's Hospital · Seattle Children's Hospital

Trials 1

today NCT04836390 · Ph 2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04836390 Aug 2021 → May 2026 overdue acute myeloid leukemia Michael Pulsipher Enrolling by invitation No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions ClinicalTrials.gov intervention name — accepted as the source's own label NCT04836390 ↗
Modality Cell therapy “three fixed dose (1 x 108/kg) infusions of ex-vivo expanded human leukocyte antigen (HLA)-haploidentical donor natural killer (NK) cells (haploNK)” NCT04836390 ↗